Other formats:
BibTeX
LaTeX
RIS
@article{766524,
author = {Höschl, Cyril and Švestka, Jaromír},
article_number = {4},
keywords = {escitalopram; major depression; anxiety disorders},
language = {eng},
issn = {1473-7175},
journal = {Expert Rev. Neurotherapeutics},
title = {Escitalopram for the treatment of major depression and anxiety disorders},
volume = {8},
year = {2008}
}
TY - JOUR
ID - 766524
AU - Höschl, Cyril - Švestka, Jaromír
PY - 2008
TI - Escitalopram for the treatment of major depression and anxiety disorders
JF - Expert Rev. Neurotherapeutics
VL - 8
IS - 4
SP - 537-552
EP - 537-552
SN - 14737175
KW - escitalopram
KW - major depression
KW - anxiety disorders
N2 - Escitalopram is the S-enantiomer of the selective serotonin reuptake inhibitor (SSRI) citalopram, which contains equal amounts of the S- and R-forms in a racemic mixture. Escitalopram is the most selective SSRI, with almost no significant affinity to other tested receptors. It has been demonstrated that it is escitalopram that carries the therapeutic potential of citalopram, and has statistically superior and clinically relevant properties compared with citalopram. Escitalopram is at least as effective in the treatment of depression and anxiety as other SSRIs, as well as venlafaxine, bupropion and duloxetine. Owing to multiple metabolic degrading pathways, the clinically relevant interactions of escitalopram with other drugs are minimal. Compared with other antidepressants, escitalopram is generally better tolerated, its onset of action is relatively fast, and its use may have cost–effectiveness and cost–utility advantages. Escitalopram is an effective first-line option in the management of patients with major depression, including severe forms, and various anxiety disorders.
ER -
HÖSCHL, Cyril and Jaromír ŠVESTKA. Escitalopram for the treatment of major depression and anxiety disorders. \textit{Expert Rev. Neurotherapeutics}. 2008, vol.~8, No~4, p.~537-552. ISSN~1473-7175.
|
